Al-Kafaji Ghada, Al-Muhtaresh Haifa Abdulla, Salem Abdel Halim
Department of Molecular Medicine/Al-Jawhara Centre for Molecular Medicine, Genetics, and Inherited Disorders, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain.
Department of Anatomy, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain.
Biomed Rep. 2021 Mar;14(3):33. doi: 10.3892/br.2021.1409. Epub 2021 Feb 3.
Pre-diabetes represents an intermediate state of altered glucose metabolism between normal glucose levels and type 2 diabetes mellitus (T2D), and is considered a significant risk factor for the development of T2D and related complications. Early detection of pre-diabetes may allow for the use of timely and effective treatment strategies to prevent its progression. Circulating microRNAs (miRNAs/miRs) that reflect changes in diabetes-related tissues, including the pancreas, liver, skeletal and heart muscle, and adipose tissue are promising biomarkers of disease progression. In our previous study, it was demonstrated that the cardiac and skeletal muscle specific miR-1 and miR-133 are upregulated in the blood of patients with T2D and cardiovascular disease. Since both miRNAs have been shown to be implicated in insulin resistance, an important feature of pre-diabetes, we hypothesised that their expression may be increased prior to clinical diagnosis of T2D, and may thus serve as biomarkers for pre-diabetes. The expression levels of circulating miRNAs were evaluated by reverse transcription-quantitative PCR in whole blood samples from 55 subjects, including 28 pre-diabetes individuals with impaired fasting glucose (FG) and impaired glucose tolerance, and 27 healthy controls. The individuals with pre-diabetes exhibited significantly higher expression levels of miR-1 and miR-133 compared with the controls (P<0.05). Target prediction search revealed that both miR-1 and miR-133 target several pathways involved in the pathophysiology of diabetes. Pearson's correlation analysis revealed that the two miRNAs were positively correlated with blood glucose parameters, including FG, 2-h oral glucose tolerance test and glycated haemoglobin A1c levels, as well as with insulin resistance (P<0.05). Multivariate logistic regression analysis revealed that the two miRNAs were significantly and directly associated with pre-diabetes, and this association remained significant after adjustment for several confounding variables (P<0.05). Moreover, linear regression analysis showed that the Homeostatic Model Assessment-Insulin Resistance was the only significant predictor to be significantly associated with both miRNAs (P<0.05). In discriminating pre-diabetes individuals from healthy controls, the area under the curves (AUCs) of the receiver operating characteristic curves (ROCs) were 0.813 and 0.810 for miR-1 and miR-133 respectively (P<0.05). Despite the relatively small number of participants, the present study showed for the first time that circulating levels of miR-1 and miR-133 were increased in individuals with pre-diabetes, and they were associated with important features of pre-diabetes. Thus, they may serve as clinical biomarkers for the early-stages of T2D.
糖尿病前期代表了正常血糖水平与2型糖尿病(T2D)之间葡萄糖代谢改变的中间状态,被认为是T2D及其相关并发症发生的重要危险因素。早期检测糖尿病前期可能有助于采用及时有效的治疗策略来预防其进展。反映糖尿病相关组织(包括胰腺、肝脏、骨骼肌、心肌和脂肪组织)变化的循环微小RNA(miRNA/miR)是疾病进展的有前景的生物标志物。在我们之前的研究中,已证明T2D和心血管疾病患者血液中心肌和骨骼肌特异性的miR-1和miR-133上调。由于这两种miRNA均已被证明与胰岛素抵抗有关,而胰岛素抵抗是糖尿病前期的一个重要特征,我们推测它们的表达可能在T2D临床诊断之前就已升高,因此可能作为糖尿病前期的生物标志物。通过逆转录定量PCR对55名受试者全血样本中循环miRNA的表达水平进行了评估,其中包括28名空腹血糖(FG)受损和糖耐量受损的糖尿病前期个体以及27名健康对照。与对照组相比,糖尿病前期个体的miR-1和miR-133表达水平显著更高(P<0.05)。靶标预测搜索显示,miR-1和miR-133均靶向糖尿病病理生理学中涉及的多个途径。Pearson相关性分析显示,这两种miRNA与血糖参数(包括FG、2小时口服葡萄糖耐量试验和糖化血红蛋白A1c水平)以及胰岛素抵抗呈正相关(P<0.05)。多变量逻辑回归分析显示,这两种miRNA与糖尿病前期显著且直接相关,在对多个混杂变量进行调整后,这种关联仍然显著(P<0.05)。此外,线性回归分析表明,稳态模型评估-胰岛素抵抗是与这两种miRNA均显著相关的唯一重要预测因子(P<0.05)。在区分糖尿病前期个体与健康对照时,miR-1和miR-133的受试者工作特征曲线(ROC)的曲线下面积(AUC)分别为0.813和0.810(P<0.05)。尽管参与者数量相对较少,但本研究首次表明,糖尿病前期个体循环中的miR-1和miR-133水平升高,且它们与糖尿病前期的重要特征相关。因此,它们可能作为T2D早期阶段的临床生物标志物。